The Technical Analyst
Select Language :
Sol Gel Technologies Ltd [SLGL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Sol Gel Technologies Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Sol Gel Technologies Ltd is listed at the  Exchange

-3.91% $0.980

America/New_York / 28 mar 2024 @ 16:00


Sol Gel Technologies Ltd: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 27.30 mill
EPS: -1.010
P/E: -0.970
Earnings Date: May 10, 2024
SharesOutstanding: 27.86 mill
Avg Daily Volume: 0.0274 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.970 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.17x
Company: PE -0.970 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.0507
(-94.83%) $-0.929
Date: 2024-03-29
Expected Trading Range (DAY)

$ 0.854 - 1.106

( +/- 12.86%)
ATR Model: 14 days

Forecast: 15:57 - $0.985

Live Trading Signals (every 1 min)

Forecast 1: 14:27 - $0.994
Forecast 2: 15:17 - $0.982
Forecast 3: 15:57 - $0.985
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
Volume Signals
Price $0.980 (-3.91% )
Volume 0.0197 mill
Avg. Vol. 0.0274 mill
% of Avg. Vol 71.71 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Sol Gel Technologies Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Sol Gel Technologies Ltd

RSI

Last 10 Buy & Sell Signals For SLGL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Sol Gel Technologies Ltd

SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Last 10 Buy Signals

Date Signal @
DYDXUSDMar 29 - 04:003.39
^KLSEMar 29 - 03:46PTS1 536.68
WSTETHUSDMar 29 - 03:594 101.01
WANETHUSDMar 29 - 03:533 523.63
KUBUSDMar 29 - 03:532.73
WTAOUSDMar 29 - 03:53524.24
NULSUSDMar 29 - 03:52$0.866
FLUXUSDMar 29 - 03:51$1.340
RADUSDMar 29 - 03:49$3.40
BTC2X-FLIUSDMar 29 - 03:5031.58

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.